# Public summary document

**Product:** ConvaTec Sur-Fit Natura Urostomy Pouch

**Applicant:** ConvaTec Australia Pty Ltd

**Date of SPAP Meeting:** 26 April 2022

## Proposed Listing on the Stoma Appliance Scheme

The applicant, ConvaTec Australia Pty Ltd, sought listing of the ConvaTec Sur-Fit Natura Urostomy Pouch in subgroup 7(a) of the Stoma Appliance Scheme (SAS) Schedule. The product (6 variants) was proposed for listing at a unit price of $3.504, with a maximum monthly quantity of 60 units.

## Comparator

The applicant nominated ConvaTec Sur-Fit Autolock (SAS Code 3747F) as the comparator. The product is currently listed in subgroup 7(a) of the SAS Schedule at the unit price of $3.504, with a maximum monthly quantity of 60 units.

## Background

This was the Stoma Product Assessment Panel’s (the Panel) first consideration of this product.

## Clinical Place for the Product

The proposed product provides an alternative for those users requiring a two-piece urostomy pouch.

## Clinical Analysis

The Panel noted that the proposed product is a replacement for the comparator, Sur-Fit Autolock (SAS Code 3747F) which is to be deleted from the SAS Schedule in 2022. The sponsor ConvaTec stated that no further clinical evidence is warranted due to the new product being comparable to the predecessor.

## Economic Analysis

The Panel noted that the proposed product is a replacement for the comparator, Sur-Fit Autolock (SAS Code 3747F) and the sponsor ConvaTec stated that no economic analysis is required due to the new product being comparable to the predecessor.

## Financial Analysis

Listing of this product unlikely to have a budgetary impact for the SAS.

## SPAP Recommendation

The Panel recommended that the ConvaTec Sur-Fit Urostomy Pouch be listed in subgroup 7(a) of the SAS Schedule with 6 variants, at the unit price of $3.504, with a maximum monthly quantity of 60 units.

## Context for Recommendation

The Panel provides advice on whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. Applications are considered in this context. Panel advice not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following advice not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Government approval.

## Applicant’s Comment

The applicant noted the SPAP recommendation.